Vanda Pharmaceuticals (VNDA) Stock Forecast, Price Target & Predictions
VNDA Stock Forecast
Vanda Pharmaceuticals stock forecast is as follows: an average price target of $11.00 (represents a 123.58% upside from VNDA’s last price of $4.92) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
VNDA Price Target
The average price target for Vanda Pharmaceuticals (VNDA) is $11.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 123.58% upside from VNDA's last price of $4.92.
VNDA Analyst Ratings
According to 2 Wall Street analysts, Vanda Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for VNDA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vanda Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 11, 2024 | Charles Duncan | Cantor Fitzgerald | $11.00 | $5.21 | 111.13% | 123.58% |
The latest Vanda Pharmaceuticals stock forecast, released on Jul 11, 2024 by Charles Duncan from Cantor Fitzgerald, set a price target of $11.00, which represents a 111.13% increase from the stock price at the time of the forecast ($5.21), and a 123.58% increase from VNDA last price ($4.92).
Vanda Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $11.00 |
| Last Closing Price | $4.92 | $4.92 | $4.92 |
| Upside/Downside | -100.00% | -100.00% | 123.58% |
In the current month, the average price target of Vanda Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vanda Pharmaceuticals's last price of $4.92. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 11, 2024 | Cantor Fitzgerald | - | Overweight | Initialise |
| Apr 26, 2022 | Zacks Investment Research | - | Hold | Upgrade |
Vanda Pharmaceuticals's last stock rating was published by Cantor Fitzgerald on Jul 11, 2024. The company Initialise its VNDA rating from "null" to "Overweight".
Vanda Pharmaceuticals Financial Forecast
Vanda Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $38.81M | $46.06M | $62.50M | $64.48M | $65.32M | $64.39M | $60.19M | $68.02M | $70.09M | $67.90M | $62.67M | $67.65M | $60.31M | $62.21M | $58.00M | $60.93M | $59.48M | $59.06M | $47.71M | $43.59M | $37.41M |
| Avg Forecast | $80.92M | $75.51M | $67.45M | $61.02M | $52.25M | $49.17M | $47.90M | $48.50M | $37.00M | $44.50M | $49.00M | $73.37M | $67.60M | $71.00M | $67.00M | $58.00M | $70.04M | $74.25M | $69.75M | $64.20M | $64.00M | $64.20M | $61.95M | $56.87M | $59.58M | $58.33M | $54.18M | $51.74M | $123.51M | $41.82M |
| High Forecast | $88.44M | $82.52M | $73.71M | $63.55M | $54.30M | $49.96M | $52.35M | $53.00M | $40.44M | $48.63M | $53.55M | $88.04M | $73.88M | $71.00M | $67.00M | $58.00M | $70.04M | $74.25M | $69.75M | $64.20M | $64.00M | $64.20M | $61.95M | $56.87M | $59.58M | $58.33M | $54.18M | $51.74M | $148.21M | $50.18M |
| Low Forecast | $74.80M | $69.80M | $62.35M | $58.49M | $50.20M | $48.38M | $44.28M | $44.83M | $34.20M | $41.14M | $45.30M | $58.70M | $62.49M | $71.00M | $67.00M | $58.00M | $70.04M | $74.25M | $69.75M | $64.20M | $64.00M | $64.20M | $61.95M | $56.87M | $59.58M | $58.33M | $54.18M | $51.74M | $98.81M | $33.45M |
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.87% | 0.94% | 0.85% | 0.95% | 0.92% | 0.96% | 1.04% | 0.97% | 0.94% | 0.97% | 0.98% | 1.06% | 0.94% | 1.00% | 1.02% | 1.02% | 1.02% | 1.09% | 0.92% | 0.35% | 0.89% |
Vanda Pharmaceuticals's average Quarter revenue forecast for Dec 23 based on 1 analysts is $37.00M, with a low forecast of $34.20M, and a high forecast of $40.44M. VNDA's average Quarter revenue forecast represents a -4.68% decrease compared to the company's last Quarter revenue of $38.81M (Sep 23).
Vanda Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-6.00M | $-2.87M | $2.67M | $7.01M | $4.29M | $4.15M | $-6.97M | $9.32M | $11.43M | $13.32M | $11.14M | $10.16M | $9.12M | $11.80M | $1.96M | $6.54M | $13.00M | $12.26M | $110.00K | $3.77M | $-6.92M |
| Avg Forecast | $6.16M | $5.75M | $5.14M | $4.65M | $3.98M | $3.74M | $3.65M | $-80.75M | $2.82M | $3.39M | $3.73M | $-73.41M | $6.83M | $5.18M | $4.89M | $-58.03M | $5.11M | $5.42M | $5.09M | $11.14M | $4.67M | $4.68M | $21.24M | $4.15M | $4.35M | $4.26M | $3.95M | $212.14K | $7.97M | $-7.65M |
| High Forecast | $6.73M | $6.28M | $5.61M | $4.84M | $4.13M | $3.80M | $3.99M | $-64.60M | $3.08M | $3.70M | $4.08M | $-58.72M | $8.20M | $5.18M | $4.89M | $-46.42M | $5.11M | $5.42M | $5.09M | $13.37M | $4.67M | $4.68M | $25.49M | $4.15M | $4.35M | $4.26M | $3.95M | $254.57K | $9.57M | $-6.12M |
| Low Forecast | $5.70M | $5.32M | $4.75M | $4.45M | $3.82M | $3.68M | $3.37M | $-96.90M | $2.60M | $3.13M | $3.45M | $-88.09M | $5.47M | $5.18M | $4.89M | $-69.63M | $5.11M | $5.42M | $5.09M | $8.91M | $4.67M | $4.68M | $16.99M | $4.15M | $4.35M | $4.26M | $3.95M | $169.71K | $6.38M | $-9.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | -1.77% | -0.77% | -0.04% | 1.03% | 0.83% | 0.85% | 0.12% | 1.82% | 2.11% | 2.62% | 1.00% | 2.18% | 1.95% | 0.56% | 0.47% | 1.51% | 3.06% | 3.10% | 0.52% | 0.47% | 0.90% |
1 analysts predict VNDA's average Quarter EBITDA for Jun 23 to be $3.73M, with a high of $4.08M and a low of $3.45M. This is 39.55% upper than Vanda Pharmaceuticals's previous annual EBITDA (Mar 23) of $2.67M.
Vanda Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | $137.00K | $1.52M | $3.25M | $6.86M | $3.27M | $2.57M | $-6.43M | $7.08M | $7.77M | $9.65M | $8.65M | $8.19M | $5.95M | $8.71M | $486.00K | $4.22M | $100.42M | $11.53M | $-612.00K | $3.07M | $-7.64M |
| Avg Forecast | $5.24M | $4.27M | $1.17M | $-1.17M | $-5.69M | $-9.13M | $-11.07M | $-72.47M | $-5.24M | $-2.33M | $-7.57M | $-65.88M | $5.19M | $5.82M | $8.15M | $-52.08M | $4.95M | $11.06M | $8.73M | $8.65M | $8.22M | $5.55M | $15.69M | $-1.75M | $4.66M | $4.37M | $2.52M | $-1.18M | $6.49M | $-8.45M |
| High Forecast | $5.88M | $4.79M | $1.31M | $-971.03K | $-5.60M | $-8.23M | $-9.98M | $-57.98M | $-4.73M | $-2.10M | $-6.83M | $-52.71M | $6.23M | $5.82M | $8.15M | $-41.67M | $4.95M | $11.06M | $8.73M | $10.38M | $8.22M | $5.55M | $18.82M | $-1.75M | $4.66M | $4.37M | $2.52M | $-944.23K | $7.79M | $-6.76M |
| Low Forecast | $4.73M | $3.85M | $1.05M | $-1.26M | $-5.77M | $-10.23M | $-12.41M | $-86.97M | $-5.88M | $-2.61M | $-8.49M | $-79.06M | $4.15M | $5.82M | $8.15M | $-62.50M | $4.95M | $11.06M | $8.73M | $6.92M | $8.22M | $5.55M | $12.55M | $-1.75M | $4.66M | $4.37M | $2.52M | $-1.42M | $5.19M | $-10.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.06% | -0.20% | -0.05% | 1.32% | 0.56% | 0.32% | 0.12% | 1.43% | 0.70% | 1.11% | 1.00% | 1.00% | 1.07% | 0.56% | -0.28% | 0.91% | 23.00% | 4.57% | 0.52% | 0.47% | 0.90% |
Vanda Pharmaceuticals's average Quarter net income forecast for Dec 23 is $-5.24M, with a range of $-5.88M to $-4.73M. VNDA's average Quarter net income forecast represents a -3927.43% decrease compared to the company's last Quarter net income of $137.00K (Sep 23).
Vanda Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | $24.77M | $28.40M | $36.10M | $32.78M | $29.85M | $33.00M | $40.85M | $33.45M | $32.46M | $28.35M | $29.80M | $59.30M | $34.37M | $34.29M | $37.39M | $37.39M | $30.60M | $31.85M | $31.41M | $27.17M | $30.75M |
| Avg Forecast | $44.05M | $41.10M | $36.71M | $33.21M | $28.44M | $26.76M | $26.07M | $26.40M | $20.14M | $24.22M | $26.67M | $39.93M | $24.53M | $38.64M | $36.47M | $31.57M | $38.12M | $40.41M | $37.96M | $29.80M | $34.83M | $34.94M | $61.71M | $30.95M | $32.43M | $31.75M | $29.49M | $28.16M | $57.54M | $33.99M |
| High Forecast | $48.14M | $44.92M | $40.12M | $34.59M | $29.55M | $27.19M | $28.49M | $28.85M | $22.01M | $26.47M | $29.15M | $47.92M | $29.43M | $38.64M | $36.47M | $31.57M | $38.12M | $40.41M | $37.96M | $35.76M | $34.83M | $34.94M | $74.06M | $30.95M | $32.43M | $31.75M | $29.49M | $28.16M | $69.05M | $40.79M |
| Low Forecast | $40.72M | $37.99M | $33.94M | $31.84M | $27.32M | $26.33M | $24.10M | $24.40M | $18.62M | $22.39M | $24.65M | $31.95M | $19.62M | $38.64M | $36.47M | $31.57M | $38.12M | $40.41M | $37.96M | $23.84M | $34.83M | $34.94M | $49.37M | $30.95M | $32.43M | $31.75M | $29.49M | $28.16M | $46.04M | $27.19M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.06% | 0.90% | 1.34% | 0.77% | 0.90% | 1.29% | 0.88% | 0.80% | 0.75% | 1.00% | 1.70% | 0.98% | 0.56% | 1.21% | 1.15% | 0.96% | 1.08% | 1.12% | 0.47% | 0.90% |
Vanda Pharmaceuticals's average Quarter SG&A projection for Dec 23 is $20.14M, based on 1 Wall Street analysts, with a range of $18.62M to $22.01M. The forecast indicates a -18.69% fall compared to VNDA last annual SG&A of $24.77M (Sep 23).
Vanda Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 20 | 9 | 9 | 9 | 9 | 10 | 10 | 10 | 10 | 10 | 10 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | $0.03 | $0.06 | $0.12 | $0.06 | $0.05 | $-0.11 | $0.13 | $0.14 | $0.17 | $0.16 | $0.15 | $0.11 | $0.16 | $0.01 | $0.08 | $1.88 | $0.22 | $-0.01 | $0.07 | $-0.17 |
| Avg Forecast | $0.09 | $0.07 | $0.02 | $-0.02 | $-0.10 | $-0.16 | $-0.19 | $0.05 | $-0.09 | $-0.04 | $-0.13 | $-0.10 | $0.08 | $0.10 | $0.14 | $-0.01 | $0.09 | $0.19 | $0.15 | $0.08 | $0.14 | $0.10 | $0.06 | $-0.03 | $0.08 | $0.07 | $0.04 | $0.07 | $-0.36 | $-0.21 |
| High Forecast | $0.10 | $0.08 | $0.02 | $-0.02 | $-0.10 | $-0.14 | $-0.17 | $0.06 | $-0.08 | $-0.04 | $-0.12 | $-0.08 | $0.09 | $0.10 | $0.14 | $-0.01 | $0.09 | $0.19 | $0.15 | $0.08 | $0.14 | $0.10 | $0.06 | $-0.03 | $0.08 | $0.07 | $0.04 | $0.07 | $-0.29 | $-0.17 |
| Low Forecast | $0.08 | $0.07 | $0.02 | $-0.02 | $-0.10 | $-0.18 | $-0.21 | $0.05 | $-0.10 | $-0.04 | $-0.15 | $-0.13 | $0.07 | $0.10 | $0.14 | $-0.01 | $0.09 | $0.19 | $0.15 | $0.08 | $0.14 | $0.10 | $0.06 | $-0.03 | $0.08 | $0.07 | $0.04 | $0.07 | $-0.43 | $-0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | -0.06% | -0.20% | -0.57% | 1.50% | 0.60% | 0.36% | 11.00% | 1.53% | 0.74% | 1.13% | 2.00% | 1.06% | 1.15% | 2.90% | -0.33% | 1.00% | 25.07% | 5.08% | -0.14% | -0.19% | 0.81% |
According to 1 Wall Street analysts, Vanda Pharmaceuticals's projected average Quarter EPS for Dec 23 is $-0.09, with a low estimate of $-0.10 and a high estimate of $-0.08. This represents a -3850.00% decrease compared to VNDA previous annual EPS of - (Sep 23).
Vanda Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| RLAY | Relay Therapeutics | $4.80 | $19.40 | 304.17% | Buy |
| TIL | Instil Bio | $26.20 | $78.25 | 198.66% | Hold |
| GPCR | Structure Therapeutics | $32.78 | $92.40 | 181.88% | Buy |
| PHAT | Phathom Pharmaceuticals | $9.37 | $25.83 | 175.67% | Buy |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| NUVB | Nuvation Bio | $2.59 | $6.75 | 160.62% | Buy |
| ANNX | Annexon | $5.46 | $14.00 | 156.41% | Buy |
| CGEM | Cullinan Oncology | $13.10 | $31.50 | 140.46% | Buy |
| KZR | Kezar Life Sciences | $7.38 | $17.50 | 137.13% | Buy |
| RCUS | Arcus Biosciences | $14.51 | $33.00 | 127.43% | Buy |
| VNDA | Vanda Pharmaceuticals | $4.92 | $11.00 | 123.58% | Buy |
| REPL | Replimune Group | $10.95 | $24.20 | 121.00% | Buy |
| LEGN | Legend Biotech | $38.40 | $82.69 | 115.34% | Buy |
| LQDA | Liquidia | $10.16 | $17.17 | 69.00% | Buy |
| BMRN | BioMarin Pharmaceutical | $61.97 | $101.70 | 64.11% | Buy |
| CYTK | Cytokinetics | $51.09 | $83.23 | 62.91% | Buy |
| CNTB | Connect Biopharma | $0.98 | $1.50 | 53.06% | Buy |
| PCVX | Vaxcyte | $87.08 | $124.00 | 42.40% | Buy |
| TECH | Bio-Techne | $66.37 | $91.69 | 38.15% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| BPMC | Blueprint Medicines | $94.60 | $109.71 | 15.97% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |
| TSVT | 2seventy bio | $3.22 | $2.00 | -37.89% | Buy |